Pioglitazone Cuts Risk of Progression to Diabetes

SAN FRANCISCO — People with impaired glucose tolerance were 81% less likely to develop type 2 diabetes over a 3-year period if treated with pioglitazone, according to a prospective, randomized, double-blind, placebo-controlled study of 602 patients.